{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T02:20:49Z","timestamp":1793326849660,"version":"4.5.0"},"reference-count":111,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"am","delay-in-days":358,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01DK056626"],"award-info":[{"award-number":["R01DK056626"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01DK103046"],"award-info":[{"award-number":["R01DK103046"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01 DK133988"],"award-info":[{"award-number":["R01 DK133988"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R37DK048873"],"award-info":[{"award-number":["R37DK048873"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.jhep.2023.10.042","type":"journal-article","created":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T11:25:47Z","timestamp":1700047547000},"page":"362-377","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":115,"title":["Pharmacologic inhibition of lipogenesis for the treatment of NAFLD"],"prefix":"10.1016","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4783-8620","authenticated-orcid":false,"given":"William P.","family":"Esler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2023.10.042_bib1","doi-asserted-by":"crossref","first-page":"E462","DOI":"10.1152\/ajpendo.00064.2004","article-title":"Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population","volume":"288","author":"Szczepaniak","year":"2005","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.jhep.2023.10.042_bib2","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s00535-013-0758-5","article-title":"Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease","volume":"48","author":"Kawano","year":"2013","journal-title":"J\u00a0Gastroenterol"},{"key":"10.1016\/j.jhep.2023.10.042_bib3","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/MOL.0000000000000080","article-title":"Fatty acid sources and their fluxes as they contribute to plasma triglyceride concentrations and fatty liver in humans","volume":"25","author":"Jacome-Sosa","year":"2014","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.jhep.2023.10.042_bib4","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1194\/jlr.M200461-JLR200","article-title":"Differences in the regulation of adipose tissue and liver lipogenesis by carbohydrates in humans","volume":"44","author":"Diraison","year":"2003","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jhep.2023.10.042_bib5","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.1042\/BCJ20210071","article-title":"SREBP-1c and lipogenesis in the liver: an update1","volume":"478","author":"Ferre","year":"2021","journal-title":"Biochem J"},{"key":"10.1016\/j.jhep.2023.10.042_bib6","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1172\/JCI0215593","article-title":"SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver","volume":"109","author":"Horton","year":"2002","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jhep.2023.10.042_bib7","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/s41574-023-00809-4","article-title":"The role of ChREBP in carbohydrate sensing and NAFLD development","volume":"19","author":"Regnier","year":"2023","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"10.1016\/j.jhep.2023.10.042_bib8","first-page":"1","article-title":"Triglyceride metabolism in the liver","volume":"8","author":"Alves-Bezerra","year":"2017","journal-title":"Compr Physiol"},{"key":"10.1016\/j.jhep.2023.10.042_bib9","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1055\/s-0033-1358519","article-title":"Lipoprotein metabolism, dyslipidemia, and nonalcoholic fatty liver disease","volume":"33","author":"Cohen","year":"2013","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2023.10.042_bib10","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1172\/JCI23621","article-title":"Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease","volume":"115","author":"Donnelly","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jhep.2023.10.042_bib11","doi-asserted-by":"crossref","first-page":"E1093","DOI":"10.1152\/ajpendo.00619.2020","article-title":"Increased postprandial nonesterified fatty acid efflux from adipose tissue in prediabetes is offset by enhanced dietary fatty acid adipose trapping","volume":"320","author":"Montastier","year":"2021","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.jhep.2023.10.042_bib12","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.cmet.2007.12.009","article-title":"Selective versus total insulin resistance: a pathogenic paradox","volume":"7","author":"Brown","year":"2008","journal-title":"Cell Metab"},{"key":"10.1016\/j.jhep.2023.10.042_bib13","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1172\/JCI134165","article-title":"Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease","volume":"130","author":"Smith","year":"2020","journal-title":"J\u00a0Clin Invest"},{"issue":"2","key":"10.1016\/j.jhep.2023.10.042_bib14","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jhep.2022.09.020","article-title":"Mitochondrial alterations in fatty liver diseases","volume":"78","author":"Fromenty","year":"2023","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.10.042_bib15","doi-asserted-by":"crossref","first-page":"15430","DOI":"10.1073\/pnas.0904944106","article-title":"Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity","volume":"106","author":"Fabbrini","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhep.2023.10.042_bib16","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1053\/j.gastro.2007.11.038","article-title":"Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease","volume":"134","author":"Fabbrini","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2023.10.042_bib17","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/MOG.0000000000000927","article-title":"Advances in the genetics of nonalcoholic fatty liver disease","volume":"39","author":"Ajmera","year":"2023","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.jhep.2023.10.042_bib18","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13733","article-title":"De novo lipogenesis in non-alcoholic fatty liver disease: quantification with stable isotope tracers","volume":"52","author":"Belew","year":"2022","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.jhep.2023.10.042_bib19","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1053\/j.gastro.2013.11.049","article-title":"Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease","volume":"146","author":"Lambert","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2023.10.042_bib20","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav9701","article-title":"Targeting diacylglycerol acyltransferase 2 for the treatment of nonalcoholic steatohepatitis","volume":"11","author":"Amin","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jhep.2023.10.042_bib21","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1021\/jm201503u","article-title":"Maximizing lipophilic efficiency: the use of Free-Wilson analysis in the design of inhibitors of acetyl-CoA carboxylase","volume":"55","author":"Freeman-Cook","year":"2012","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.jhep.2023.10.042_bib22","doi-asserted-by":"crossref","first-page":"7110","DOI":"10.1021\/jm401033t","article-title":"Spirolactam-based acetyl-CoA carboxylase inhibitors: toward improved metabolic stability of a chromanone lead structure","volume":"56","author":"Griffith","year":"2013","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.jhep.2023.10.042_bib23","doi-asserted-by":"crossref","first-page":"10512","DOI":"10.1021\/jm5016022","article-title":"Decreasing the rate of metabolic ketone reduction in the discovery of a clinical acetyl-CoA carboxylase inhibitor for the treatment of diabetes","volume":"57","author":"Griffith","year":"2014","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.jhep.2023.10.042_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101196","article-title":"Pharmacologic inhibition of ketohexokinase prevents fructose-induced metabolic dysfunction","volume":"48","author":"Gutierrez","year":"2021","journal-title":"Mol Metab"},{"key":"10.1016\/j.jhep.2023.10.042_bib25","doi-asserted-by":"crossref","first-page":"E1796","DOI":"10.1073\/pnas.1520686113","article-title":"Acetyl-CoA carboxylase inhibition by ND-630 reduces hepatic steatosis, improves insulin sensitivity, and modulates dyslipidemia in rats","volume":"113","author":"Harriman","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhep.2023.10.042_bib26","doi-asserted-by":"crossref","first-page":"37099","DOI":"10.1074\/jbc.M304481200","article-title":"Isozyme-nonselective N-substituted bipiperidylcarboxamide acetyl-CoA carboxylase inhibitors reduce tissue malonyl-CoA concentrations, inhibit fatty acid synthesis, and increase fatty acid oxidation in cultured cells and in experimental animals","volume":"278","author":"Harwood","year":"2003","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jhep.2023.10.042_bib27","article-title":"FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models","volume":"12","author":"O'Farrell","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhep.2023.10.042_bib28","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1172\/JCI27300","article-title":"Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2","volume":"116","author":"Savage","year":"2006","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jhep.2023.10.042_bib29","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1038\/s41591-021-01489-1","article-title":"ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials","volume":"27","author":"Calle","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2023.10.042_bib30","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1053\/jhep.2003.50348","article-title":"Prevention of diet-induced fatty liver in experimental animals by the oral administration of a fatty acid bile acid conjugate (FABAC)","volume":"38","author":"Gilat","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.10.042_bib31","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1002\/hep.30097","article-title":"Acetyl-CoA carboxylase inhibition reverses NAFLD and hepatic insulin resistance but promotes hypertriglyceridemia in rodents","volume":"68","author":"Goedeke","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.10.042_bib32","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.cmet.2017.07.009","article-title":"Acetyl CoA carboxylase inhibition reduces hepatic steatosis but elevates plasma triglycerides in mice and humans: a bedside to bench investigation","volume":"26","author":"Kim","year":"2017","journal-title":"Cell Metab"},{"key":"10.1016\/j.jhep.2023.10.042_bib33","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jcmgh.2020.06.001","article-title":"Acetyl-CoA carboxylase inhibition improves multiple dimensions of NASH pathogenesis in model systems","volume":"10","author":"Ross","year":"2020","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2023.10.042_bib34","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.3748\/wjg.v18.i19.2300","article-title":"Animal models of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis","volume":"18","author":"Takahashi","year":"2012","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2023.10.042_bib35","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/advances\/nmy002","article-title":"Modeling the western diet for preclinical investigations","volume":"9","author":"Hintze","year":"2018","journal-title":"Adv Nutr"},{"key":"10.1016\/j.jhep.2023.10.042_bib36","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jhep.2020.04.037","article-title":"Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation","volume":"73","author":"Bates","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2023.10.042_bib37","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1038\/nm.3704","article-title":"De novo fatty acid synthesis controls the fate between regulatory T and T helper 17 cells","volume":"20","author":"Berod","year":"2014","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.jhep.2023.10.042_bib38","article-title":"Aramchol downregulates stearoyl CoA-desaturase 1 in hepatic stellate cells to attenuate cellular fibrogenesis","volume":"3","author":"Bhattacharya","year":"2021","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2023.10.042_bib39","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/nrgastro.2017.38","article-title":"Mechanisms of hepatic stellate cell activation","volume":"14","author":"Tsuchida","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2023.10.042_bib40","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.cmet.2021.04.018","article-title":"PKM2-dependent metabolic skewing of hepatic Th17 cells regulates pathogenesis of non-alcoholic fatty liver disease","volume":"33","author":"Moreno-Fernandez","year":"2021","journal-title":"Cell Metab"},{"key":"10.1016\/j.jhep.2023.10.042_bib41","doi-asserted-by":"crossref","first-page":"97","DOI":"10.4049\/jimmunol.1501175","article-title":"Progression from nonalcoholic fatty liver to nonalcoholic steatohepatitis is marked by a higher frequency of Th17 cells in the liver and an increased Th17\/resting regulatory T cell ratio in peripheral blood and in the liver","volume":"196","author":"Rau","year":"2016","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jhep.2023.10.042_bib42","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1042\/CS20150405","article-title":"The balance between IL-17 and IL-22 produced by liver-infiltrating T-helper cells critically controls NASH development in mice","volume":"130","author":"Rolla","year":"2016","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.jhep.2023.10.042_bib43","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/cpdd.782","article-title":"Tolerability, pharmacokinetics, and pharmacodynamics of a liver-targeting acetyl-CoA carboxylase inhibitor (PF-05221304): a three-Part Randomized phase 1 study","volume":"9","author":"Bergman","year":"2020","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.jhep.2023.10.042_bib44","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau8465","article-title":"Human sebum requires de novo lipogenesis, which is increased in acne vulgaris and suppressed by acetyl-CoA carboxylase inhibition","volume":"11","author":"Esler","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jhep.2023.10.042_bib45","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1002\/hep.29246","article-title":"Acetyl-coenzyme A carboxylase inhibition reduces de novo lipogenesis in overweight male subjects: a randomized, double-blind, crossover study","volume":"66","author":"Stiede","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.10.042_bib46","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/hep.31000","article-title":"Fatty acid synthase inhibitor TVB-2640 reduces hepatic de Novo lipogenesis in males with metabolic abnormalities","volume":"72","author":"Syed-Abdul","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.10.042_bib47","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jhep.2022.04.003","article-title":"Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: a randomised, open-label phase II trial","volume":"77","author":"Alkhouri","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.10.042_bib48","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.medj.2021.04.007","article-title":"Inhibition of ketohexokinase in adults with NAFLD reduces liver fat and inflammatory markers: a randomized phase 2 trial","volume":"2","author":"Kazierad","year":"2021","journal-title":"Med"},{"issue":"5","key":"10.1016\/j.jhep.2023.10.042_bib49","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1053\/j.gastro.2018.07.027","article-title":"Reduces hepatic steatosis and fibrosis markers in patients with nonalcoholic fatty liver disease","volume":"155","author":"Loomba","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2023.10.042_bib50","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1053\/j.gastro.2021.07.025","article-title":"TVB-2640 (FASN inhibitor) for the treatment of nonalcoholic steatohepatitis: FASCINATE-1, a randomized, placebo-controlled phase 2a trial","volume":"161","author":"Loomba","year":"2021","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.jhep.2023.10.042_bib51","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S2468-1253(20)30186-2","article-title":"Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial","volume":"5","author":"Loomba","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2023.10.042_bib52","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1016\/j.cgh.2014.04.038","article-title":"The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease","volume":"12","author":"Safadi","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2023.10.042_bib53","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1111\/dom.14946","article-title":"A\u00a0phase 2a, randomized, double-blind, placebo-controlled, three-arm, parallel-group study to assess the efficacy, safety, tolerability and pharmacodynamics of PF-06835919 in patients with non-alcoholic fatty liver disease and type 2 diabetes","volume":"25","author":"Saxena","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jhep.2023.10.042_bib54","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1038\/sj.ejcn.1600744","article-title":"De novo lipogenesis in humans: metabolic and regulatory aspects","volume":"53","author":"Hellerstein","year":"1999","journal-title":"Eur J Clin Nutr"},{"key":"10.1016\/j.jhep.2023.10.042_bib55","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1172\/JCI115206","article-title":"Measurement of de novo hepatic lipogenesis in humans using stable isotopes","volume":"87","author":"Hellerstein","year":"1991","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jhep.2023.10.042_bib56","doi-asserted-by":"crossref","first-page":"E126","DOI":"10.1152\/ajpendo.00470.2017","article-title":"Dose-dependent quantitative effects of acute fructose administration on hepatic de novo lipogenesis in healthy humans","volume":"315","author":"Beysen","year":"2018","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.jhep.2023.10.042_bib57","first-page":"E1146","article-title":"Mass isotopomer distribution analysis at eight years: theoretical, analytic, and experimental considerations","volume":"276","author":"Hellerstein","year":"1999","journal-title":"Am J Physiol"},{"key":"10.1016\/j.jhep.2023.10.042_bib58","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/hep.29797","article-title":"Noninvasive, quantitative assessment of liver fat by MRI-PDFF as an endpoint in NASH trials","volume":"68","author":"Caussy","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.10.042_bib59","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1016\/j.cgh.2020.08.061","article-title":"Change in MRI-PDFF and histologic response in patients with nonalcoholic steatohepatitis: a systematic review and meta-analysis","volume":"19","author":"Stine","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2023.10.042_bib60","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1146\/annurev.nutr.28.061807.155434","article-title":"Malonyl-CoA, a key signaling molecule in mammalian cells","volume":"28","author":"Saggerson","year":"2008","journal-title":"Annu Rev Nutr"},{"key":"10.1016\/j.jhep.2023.10.042_bib61","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1172\/JCI108764","article-title":"A\u00a0possible role for malonyl-CoA in the regulation of hepatic fatty acid oxidation and ketogenesis","volume":"60","author":"McGarry","year":"1977","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jhep.2023.10.042_bib62","doi-asserted-by":"crossref","first-page":"4011","DOI":"10.1073\/pnas.92.9.4011","article-title":"Human acetyl-CoA carboxylase: characterization, molecular cloning, and evidence for two isoforms","volume":"92","author":"Abu-Elheiga","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"10.1016\/j.jhep.2023.10.042_bib63","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1016\/j.bmcl.2009.04.091","article-title":"Discovery of small molecule isozyme non-specific inhibitors of mammalian acetyl-CoA carboxylase 1 and 2","volume":"20","author":"Corbett","year":"2010","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.jhep.2023.10.042_bib64","first-page":"27","article-title":"Hepatic fibrosis--role of hepatic stellate cell activation","volume":"4","author":"Safadi","year":"2002","journal-title":"MedGenMed"},{"key":"10.1016\/j.jhep.2023.10.042_bib65","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0228212","article-title":"Acetyl-CoA carboxylase 1 and 2 inhibition ameliorates steatosis and hepatic fibrosis in a MC4R knockout murine model of nonalcoholic steatohepatitis","volume":"15","author":"Matsumoto","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2023.10.042_bib66","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1124\/jpet.121.000786","article-title":"Selective acetyl-CoA carboxylase 1 inhibitor improves hepatic steatosis and hepatic fibrosis in a preclinical nonalcoholic steatohepatitis model","volume":"379","author":"Tamura","year":"2021","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.jhep.2023.10.042_bib67","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1038\/s42255-020-00272-9","article-title":"De novo lipogenesis is essential for platelet production in humans","volume":"2","author":"Kelly","year":"2020","journal-title":"Nat Metab"},{"key":"10.1016\/j.jhep.2023.10.042_bib68","doi-asserted-by":"crossref","first-page":"10879","DOI":"10.1021\/acs.jmedchem.0c00640","article-title":"Optimizing the benefit\/risk of acetyl-CoA carboxylase inhibitors through liver targeting","volume":"63","author":"Huard","year":"2020","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.jhep.2023.10.042_bib69","doi-asserted-by":"crossref","first-page":"16480","DOI":"10.1073\/pnas.0706794104","article-title":"Continuous fat oxidation in acetyl-CoA carboxylase 2 knockout mice increases total energy expenditure, reduces fat mass, and improves insulin sensitivity","volume":"104","author":"Choi","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhep.2023.10.042_bib70","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1007\/s00125-012-2554-9","article-title":"Inhibition of acetyl-CoA carboxylase 2 enhances skeletal muscle fatty acid oxidation and improves whole-body glucose homeostasis in db\/db mice","volume":"55","author":"Glund","year":"2012","journal-title":"Diabetologia"},{"key":"10.1016\/j.jhep.2023.10.042_bib71","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/j.1463-1326.2009.01078.x","article-title":"Soraphen, an inhibitor of the acetyl-CoA carboxylase system, improves peripheral insulin sensitivity in mice fed a high-fat diet","volume":"11","author":"Schreurs","year":"2009","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jhep.2023.10.042_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174451","article-title":"Acetyl-CoA carboxylase 2 inhibition reduces skeletal muscle bioactive lipid content and attenuates progression of type 2 diabetes in Zucker diabetic fatty rats","volume":"910","author":"Takagi","year":"2021","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jhep.2023.10.042_bib73","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1124\/jpet.119.263590","article-title":"A\u00a0novel acetyl-CoA carboxylase 2 selective inhibitor improves whole-body insulin resistance and hyperglycemia in diabetic mice through target-dependent pathways","volume":"372","author":"Takagi","year":"2020","journal-title":"J\u00a0Pharmacol Exp Ther"},{"issue":"4","key":"10.1016\/j.jhep.2023.10.042_bib74","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.molmet.2014.02.004","article-title":"Genetic inhibition of hepatic acetyl-CoA carboxylase activity increases liver fat and alters global protein acetylation","volume":"3","author":"Chow","year":"2014","journal-title":"Mol Metab"},{"key":"10.1016\/j.jhep.2023.10.042_bib75","doi-asserted-by":"crossref","first-page":"8552","DOI":"10.1073\/pnas.0603115103","article-title":"Liver-specific deletion of acetyl-CoA carboxylase 1 reduces hepatic triglyceride accumulation without affecting glucose homeostasis","volume":"103","author":"Mao","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhep.2023.10.042_bib76","doi-asserted-by":"crossref","first-page":"10132","DOI":"10.1021\/jm401601s","article-title":"Piperazine oxadiazole inhibitors of acetyl-CoA carboxylase","volume":"56","author":"Bourbeau","year":"2013","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.jhep.2023.10.042_bib77","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00125-018-4743-7","article-title":"Disruption of beta cell acetyl-CoA carboxylase-1 in mice impairs insulin secretion and beta cell mass","volume":"62","author":"Cantley","year":"2019","journal-title":"Diabetologia"},{"key":"10.1016\/j.jhep.2023.10.042_bib78","doi-asserted-by":"crossref","first-page":"14248","DOI":"10.1074\/jbc.M800119200","article-title":"Chronic suppression of acetyl-CoA carboxylase 1 in beta-cells impairs insulin secretion via inhibition of glucose rather than lipid metabolism","volume":"283","author":"Ronnebaum","year":"2008","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jhep.2023.10.042_bib79","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-056159","volume":"12","author":"Amin","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.jhep.2023.10.042_bib80","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/hep.31622","article-title":"Combination therapies including cilofexor and firsocostat for bridging fibrosis and cirrhosis attributable to NASH","volume":"73","author":"Loomba","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.10.042_bib81","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0140-6736(14)61177-6","article-title":"Triglycerides and cardiovascular disease","volume":"384","author":"Nordestgaard","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2023.10.042_bib82","doi-asserted-by":"crossref","first-page":"3935","DOI":"10.3390\/molecules25173935","article-title":"Fatty acid synthase: an emerging target in cancer","volume":"25","author":"Fhu","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.jhep.2023.10.042_bib83","doi-asserted-by":"crossref","first-page":"5378","DOI":"10.1073\/pnas.1002588108","article-title":"Antidiabetic and antisteatotic effects of the selective fatty acid synthase (FAS) inhibitor platensimycin in mouse models of diabetes","volume":"108","author":"Wu","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhep.2023.10.042_bib84","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.tem.2017.10.003","article-title":"Insights into stearoyl-CoA desaturase-1 regulation of systemic metabolism","volume":"28","author":"AL","year":"2017","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.jhep.2023.10.042_bib85","doi-asserted-by":"crossref","first-page":"168","DOI":"10.4254\/wjh.v14.i1.168","article-title":"Stearoyl-CoA desaturase 1: a potential target for non-alcoholic fatty liver disease?-perspective on emerging experimental evidence","volume":"14","author":"Jeyakumar","year":"2022","journal-title":"World J Hepatol"},{"key":"10.1016\/j.jhep.2023.10.042_bib86","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.2174\/138920012803762693","article-title":"Recent advances on stearoyl-Coa desaturase regulation in fatty liver diseases","volume":"13","author":"Narce","year":"2012","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.jhep.2023.10.042_bib87","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.arcmed.2010.09.001","article-title":"Fatty acid bile acid conjugate inhibits hepatic stearoyl coenzyme A desaturase and is non-atherogenic","volume":"41","author":"Leikin-Frenkel","year":"2010","journal-title":"Arch Med Res"},{"key":"10.1016\/j.jhep.2023.10.042_bib88","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1002\/hep4.1107","article-title":"Role of Aramchol in steatohepatitis and fibrosis in mice","volume":"1","author":"Iruarrizaga-Lejarreta","year":"2017","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2023.10.042_bib89","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1042\/BJ20051694","article-title":"ABCA1-dependent but apoA-I-independent cholesterol efflux mediated by fatty acid-bile acid conjugates (FABACs)","volume":"396","author":"Goldiner","year":"2006","journal-title":"Biochem J"},{"key":"10.1016\/j.jhep.2023.10.042_bib90","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/MOL.0b013e32833854ac","article-title":"Stearoyl-coenzyme A desaturase 1 inhibition and the metabolic syndrome: considerations for future drug discovery","volume":"21","author":"Brown","year":"2010","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.jhep.2023.10.042_bib91","doi-asserted-by":"crossref","first-page":"19961","DOI":"10.1074\/jbc.M109.014225","article-title":"Skin-specific deletion of stearoyl-CoA desaturase-1 alters skin lipid composition and protects mice from high fat diet-induced obesity","volume":"284","author":"Sampath","year":"2009","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jhep.2023.10.042_bib92","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1038\/s41591-021-01495-3","article-title":"Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial","volume":"27","author":"Ratziu","year":"2021","journal-title":"Nat Med"},{"issue":"23","key":"10.1016\/j.jhep.2023.10.042_bib93","first-page":"272","article-title":"Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial","volume":"S2468\u20131253","author":"Harrison","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2023.10.042_bib94","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A\u00a0placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2023.10.042_bib95","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.jhep.2023.03.038","article-title":"An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH","volume":"79","author":"Tacke","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2023.10.042_bib96","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.clinthera.2022.12.008","article-title":"Inhibition of diacylglycerol acyltransferase 2 versus diacylglycerol acyltransferase 1: potential therapeutic implications of pharmacology","volume":"45","author":"Amin","year":"2023","journal-title":"Clin Ther"},{"key":"10.1016\/j.jhep.2023.10.042_bib97","doi-asserted-by":"crossref","first-page":"25474","DOI":"10.1074\/jbc.M202013200","article-title":"DGAT1 is not essential for intestinal triacylglycerol absorption or chylomicron synthesis","volume":"277","author":"Buhman","year":"2002","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jhep.2023.10.042_bib98","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/dom.12002","article-title":"Proof of mechanism for the DGAT1 inhibitor AZD7687: results from a first-time-in-human single-dose study","volume":"15","author":"Denison","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jhep.2023.10.042_bib99","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/dom.12221","article-title":"Diacylglycerol acyltransferase 1 inhibition with AZD7687 alters lipid handling and hormone secretion in the gut with intolerable side effects: a randomized clinical trial","volume":"16","author":"Denison","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jhep.2023.10.042_bib100","doi-asserted-by":"crossref","first-page":"9820","DOI":"10.1021\/jm4007033","article-title":"Current status of the research and development of diacylglycerol O-acyltransferase 1 (DGAT1) inhibitors","volume":"56","author":"DeVita","year":"2013","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.jhep.2023.10.042_bib101","doi-asserted-by":"crossref","first-page":"G958","DOI":"10.1152\/ajpgi.00384.2012","article-title":"Pharmacological inhibition to examine the role of DGAT1 in dietary lipid absorption in rodents and humans","volume":"304","author":"Maciejewski","year":"2013","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.jhep.2023.10.042_bib102","doi-asserted-by":"crossref","first-page":"38870","DOI":"10.1074\/jbc.M106219200","article-title":"Cloning of DGAT2, a second mammalian diacylglycerol acyltransferase, and related family members","volume":"276","author":"Cases","year":"2001","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jhep.2023.10.042_bib103","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1194\/jlr.M020156","article-title":"The use of stable isotope-labeled glycerol and oleic acid to differentiate the hepatic functions of DGAT1 and -2","volume":"53","author":"Qi","year":"2012","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jhep.2023.10.042_bib104","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/hep.20783","article-title":"Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice","volume":"42","author":"Yu","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.10.042_bib105","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/hep.21988","article-title":"Diacylglycerol acyltranferase 1 anti-sense oligonucleotides reduce hepatic fibrosis in mice with nonalcoholic steatohepatitis","volume":"47","author":"Yamaguchi","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.10.042_bib106","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1002\/hep.30765","article-title":"Hepatocyte deletion of triglyceride-synthesis enzyme acyl CoA: diacylglycerol acyltransferase 2 reduces steatosis without increasing inflammation or fibrosis in mice","volume":"70","author":"Gluchowski","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.10.042_bib107","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jcmgh.2019.04.007","article-title":"Metabolic targets in nonalcoholic fatty liver disease","volume":"8","author":"Esler","year":"2019","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2023.10.042_bib108","doi-asserted-by":"crossref","first-page":"15000","DOI":"10.1021\/acs.jmedchem.2c01200","article-title":"Discovery of ervogastat (PF-06865571): a potent and selective inhibitor of diacylglycerol acyltransferase 2 for the treatment of non-alcoholic steatohepatitis","volume":"65","author":"Futatsugi","year":"2022","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.jhep.2023.10.042_bib109","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1093\/hmg\/3.9.1627","article-title":"Molecular basis of essential fructosuria: molecular cloning and mutational analysis of human ketohexokinase (fructokinase)","volume":"3","author":"Bonthron","year":"1994","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.jhep.2023.10.042_bib110","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1016\/j.cmet.2021.09.010","article-title":"Molecular aspects of fructose metabolism and metabolic disease","volume":"33","author":"Herman","year":"2021","journal-title":"Cell Metab"},{"key":"10.1016\/j.jhep.2023.10.042_bib111","doi-asserted-by":"crossref","first-page":"13546","DOI":"10.1021\/acs.jmedchem.0c00944","article-title":"Discovery of PF-06835919: a potent inhibitor of ketohexokinase (KHK) for the treatment of metabolic disorders driven by the overconsumption of fructose","volume":"63","author":"Futatsugi","year":"2020","journal-title":"J\u00a0Med Chem"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827823052753?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827823052753?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T17:13:10Z","timestamp":1739553190000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827823052753"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":111,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S0168827823052753"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2023.10.042","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacologic inhibition of lipogenesis for the treatment of NAFLD","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2023.10.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}